Plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation: a profile of its use in the USA

被引：0

作者：

Blair H.A. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Mairangi Bay 0754, Auckland

来源：

Drugs & Therapy Perspectives | 2018年 / 34卷 / 12期

关键词：

D O I：

10.1007/s40267-018-0579-y

中图分类号：

学科分类号：

摘要：

Plecanatide (Trulance®), a guanylate cyclase C agonist, is an effective and generally well-tolerated treatment option for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It can be administered with or without food, at any time of the day. In phase 3 clinical trials, once-daily plecanatide 3 mg significantly improved stool frequency, stool consistency, clinical symptoms (e.g. straining, abdominal symptoms including pain), health-related quality of life, and treatment satisfaction. Plecanatide is generally well tolerated, with most adverse events being of mild or moderate severity. Consistent with its therapeutic action, the most common adverse event is diarrhea. © 2018, Springer Nature Switzerland AG.

引用

页码：554 / 559

页数：5

共 23 条

[1] Chey W.D., Symposium report: an evidence-based approach to IBS and CIC: applying new advances to daily practice: a review of an adjunct clinical symposium of the American College of Gastroenterology meeting October 16, 2016, Las Vegas, Nevada, Gastroenterol Hepatol., 13, pp. 1-16, (2017)
[2] Shailubhai K., Comiskey S., Foss J.A., Et al., Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses, Dig Dis Sci., 58, 9, pp. 2580-2586, (2013)
[3] Waldman S.A., Camilleri M., Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders, Gut., 67, 8, pp. 1543-1552, (2018)
[4] (2018)
[5] Shailubhai K., Palejwala V., Arjunan K.P., Et al., Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis, World J Gastrointest Pharmacol Ther., 6, 4, pp. 213-222, (2015)
[6] Shailubhai K., Beaufrand C., Palejwala V., Et al., Oral treatment with plecanatide and SP-333, agonists of guanylate cyclase-C, attenuates visceral hypersensitivity in rat models (abstract no. PP095), Neurogastroenterol Motil, 26, pp. Suppl 1-Suppl 41, (2014)
[7] Miner P.B., Koltun W.D., Wiener G.J., Et al., A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation, Am J Gastroenterol., 112, pp. 613-621, (2017)
[8] DeMicco M., Barrow L., Hickey B., Et al., Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation, Ther Adv Gastroenterol., 10, 11, pp. 837-851, (2017)
[9] Brenner D.M., Fogel R., Dorn S.D., Et al., Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials, Am J Gastroenterol., 113, 5, pp. 735-745, (2018)
[10] Rao S., Barrow L., Layton M.B., Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation (CIC): pooled results from two phase 3 studies (abstract no. 523), Am J Gastroenterol, 111, (2016)

← 1 2 3 →